Home Blog Page 2309

Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium

By
Advertorial Desk
-
  • 7 new NEFECON® real-world evidence abstracts will be presented at the 18th International lgA Nephropathy Symposium (IIgANN 2025).
  • The newly released results, based on clinical practices at several leading hospitals in China, offer a comprehensive overview of the efficacy and safety of NEFECON® in the treatment of IgA nephropathy (IgAN). NEFECON® clinical value was highlighted across three key dimensions, consistent with the new disease management strategy of “Treat the cause, Treat early, Treat long-term.” 
  • NEFECON® is currently the only etiological treatment for IgAN recommended by both domestic and international guidelines, reinforcing its position as the foundational first-line cornerstone treatment for IgAN patients.

SHANGHAI, Sept. 15, 2025 /PRNewswire/ — At the 18th International lgA Nephropathy Symposium (IIgANN 2025), 7 new abstracts based on real-world evidence of NEFECON® will be presented. The 18th IIgANN will take place in Prague, Czech Republic, from September 17 to 20, 2025.

The newly released results, based on clinical practices at several leading hospitals in China, offer a comprehensive overview of the efficacy and safety of NEFECON® in the treatment of IgA nephropathy (IgAN). The clinical value of NEFECON® was highlighted across three key dimensions, consistent with the new disease management strategy of “Treat the cause, Treat early, Treat long-term.” In real-world clinical practice, there is strong validation of NEFECON®‘s value as an etiological treatment, where early intervention is critical in reducing proteinuria and protecting renal function, and extended treatment beyond 9 months provided robust evidence supporting sustained efficacy and safety.

These real-world evidence not only address the limitations of randomized controlled trials (RCTs) in clinical practice but also reinforce the new disease management strategy of “Treat the cause, Treat early, Treat long-term”. They further strengthen NEFECON®‘s position as the world’s first etiological treatment for IgAN, providing strong scientific evidence to advance both clinical practice and global research.

NEFECON® has been recommended by several authoritative treatment guidelines, including the “KDIGO 2024 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)”, and the “Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)”. NEFECON® was included in China’s National Reimbursement Drug List (NRDL) in November 2024, and the supplemental application for the production expansion of NEFECON® has been officially approved by NMPA in August 2025.

NEFECON® is currently the world’s first IgAN treatment to have received full approval from the National Medical Products Administration (NMPA) in China, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency（MHRA）in the United Kingdom, as well as in other Asian territories where Everest Medicines holds the rights, including Hong Kong SAR, Macao SAR, Taiwan region (China), Singapore, and South Korea.

Abstracts

1.   Abstract Number: P-45
Title: Beyond Nine Months: Real-World Efficacy and Safety of Extended Nefecon Therapy in IgA Nephropathy
Principal author and institution: Chiwa Aoieong, Xiu Yang. Kiang Wu Hospital, Department of Nephrology, Macao, China; Hangzhou First People’s Hospital Affiliated to Westlake University School of Medicine, Department of Nephrology, Hangzhou, China
Abstract：The study is to assess the efficacy and safety of 12-month Nefecon therapy in IgAN patients in a real-world setting, compared to conventional treatment. In conclusion, twelve-month Nefecon therapy significantly reduced proteinuria and preserved renal function in IgAN patients, with a better safety profile compared to conventional treatment involving systemic corticosteroids and immunosuppressants.

2.   Abstract Number: P-44
Title: Efficacy and Safety of Nefecon in IgA Nephropathy: A 6-Month Retrospective Cohort Study
Principal author and institution: Shasha Chen, Guisen Li, Sichuan Academy of Medical Sciences&Sichuan Provincial People’s Hospital, Department of Nephrology, Chengdu, China.
Abstract: The study is to evaluate the clinical efficacy and safety of Nefecon (budesonide enteric capsules) in patients with IgA nephropathy (IgAN). In conclusion, Nefecon significantly reduces proteinuria and improves renal function in IgAN patients, with a favorable safety profile. These findings support its potential as a first-line therapeutic option for IgAN. Further randomized controlled trials with larger cohorts are warranted to validate these results.

3.    Abstract Number: P-43
Title: Budesonide enteric capsules* for IgA nephropathy with hepatitis B virus infection: Two cases
Principal author and institution: Shasha Chen, Guisen Li, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital，Department of Nephrology, Chengdu, China
Abstract: The study is to evaluate the efficacy and safety of budesonide enteric capsules in patients with IgAN and chronic HBV infection. In conclusion, budesonide enteric capsules combined with intensive supportive therapy effectively improved renal outcomes in IgAN patients with HBV coinfection without triggering viral reactivation. This case report provides an evidence-based support for the use of budesonide enteric capsules in the special population, suggesting that targeted intestinal immunity modulate the number and activity of mucosal B cells in ileal Peyer’s patches may be a preferred strategy under strict HBV biomarker monitoring.

* Budesonide enteric capsules are Nefecon.

4.   Abstract Number: P-63
Title: First real-world evidence of Nefecon efficacy in pediatric patients with IgA nephropathy or IgA vasculitis nephritis 
Principal author and institution: Yu Zhang, Jianhua Zhou, Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Abstract: The study is to evaluate the efficacy of Nefecon in pediatric patients with IgAN/IgAVN. In conclusion, in this real-world setting, Nefecon shows a significant impact on reducing proteinuria and hematuria in pediatric patients with IgAN/IgAVN. However, its potential inhibition of the hypothalamic-pituitary-adrenal axis remains a concern that warrants meticulous consideration by pediatric nephrologists.

5.   Abstract Number: P-64
Title: Efficacy and Safety Profile of Nefecon in 26 Chinese Patients with IgA Nephropathy: A Real-World Observational Study
Principal author and institution: Junjun Zhang, Zhanzheng Zhao, The Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Abstract: The study is to assess real-world clinical outcomes and safety of Nefecon in Chinese IgAN patients. This real-world analysis demonstrates Nefecon’s sustained renoprotective effects in Chinese IgAN patients, particularly those with preserved renal function (eGFR ≥35 mL/min/1.73m²), with progressive proteinuria reduction and hematuria resolution. The favorable safety profile supports its clinical utility in this population.

6.   Abstract Number: P-48
Title: Nefecon Treatment in Patients with Primary IgA Nephropathy and Renal Insufficiency: A 6 – Month Observational Study
Principal author and institution: Ming Fang，Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Renal Translational Medicine Center of Liaoning Province, Dalian, China
Abstract: The study is to investigate the effectiveness and safety of Nefecon in patients with IgAN and renal insufficiency. In conclusion, six-month Nefecon therapy demonstrated potential stabilization of kidney function alongside modest proteinuria reduction, with favorable tolerability in high-risk IgAN populations.

7.   Abstract Number: P-62
Title: Early Intervention with Budesonide Enteric-Coated Capsules* in IgA Nephropathy: 2 Case Demonstrating Reduced Proteinuria and Stabilized Renal Function
Principal author and institution: Xiaoyan Xiao, Qilu Hospital of Shandong University, Department of Nephrology, Jinan, Shandong, China
Abstract: The study is to evaluate its efficacy and safety in the early treatment of IgAN. In conclusion, budesonide enteric-coated capsules significantly reduced proteinuria and stabilized renal function and well tolerated in the early treatment of IgAN. Early diagnosis and treatment of patients are particularly important in IgAN.

* Budesonide enteric capsules are Nefecon.

About NEFECON®

NEFECON® is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. The formulation is designed as a delayed release capsule that is enteric coated so that it remains intact until it releases budesonide to the distal ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models.

In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas Therapeutics, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON® in mainland China, Hong Kong SAR, Macao SAR, Taiwan, China and Singapore. The agreement was extended in March 2022 to include South Korea as part of Everest Medicine’s territories.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com. 

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

30 Years of BODY WORLDS – A Success Story That Has Changed the Way We See Ourselves

By
Advertorial Desk
-

HEIDELBERG, GERMANY – Newsaktuell – 15 September 2025 – Exactly 30 years ago today, on September 15, 1995, a new chapter in the history of exhibitions was opened in Tokyo — one that remains unparalleled worldwide: the premiere of the first BODY WORLDS exhibition at the Tokyo National Science Museum, held on the occasion of the 100th Annual Meeting of the Japanese Anatomical Society.

Gunther von Hagens privat copyright: Institute for Plastination, Heidelberg/Germany
Gunther von Hagens privat copyright: Institute for Plastination, Heidelberg/Germany

What no one could have foreseen at the time: this opening marked the beginning of an extraordinary success story. BODY WORLDS made the invisible visible — for the first time, millions of visitors gained fascinating insights into the human body in a way that had never been possible before.

Since then, more than 57 million people in over 170 cities and 42 countries across six continents have experienced the exhibitions. BODY WORLDS is now considered one of the most successful and influential exhibition concepts in the world.

The foundation for this success was laid by Dr. Gunther von Hagens with the invention of Plastination. What was once reserved for medical professionals became accessible and understandable to all through his technique.

Gunther von Hagens privat copyright: Institute for Plastination, Heidelberg/Germany
Gunther von Hagens privat copyright: Institute for Plastination, Heidelberg/Germany

“From the very beginning, my goal was to democratize anatomy. I wanted to give people the opportunity to look inside themselves – not to break taboos, but as an invitation to gain knowledge of, respect, and responsibility for their own bodies,” explains von Hagens.

“BODY WORLDS has fundamentally changed the way we understand the human body and has contributed to a new culture of education about health and life,” adds Dr. Angelina Whalley, the exhibition’s curator, who has shaped the conceptual design from the start.

Even three decades after its debut, BODY WORLDS has lost none of its relevance – thanks to its universal subject: the human being. In an age of rapid change, digital overstimulation, and constant motion, the exhibition offers a rare moment of pause and reflection. Even the harsh criticism at the beginning — which emerged solely in Germany — has not changed this. Today, BODY WORLDS provides direct access to one’s own body, promotes health awareness, and encourages people to take responsibility for their lives.

It is precisely this combination of scientific education, personal relevance, and emotional impact that makes the exhibition timeless — and meaningful to every new generation.

30 Years of BODY WORLDS — a celebration of life that moves, inspires, and transforms people.

Discover our jubilee film on https://bit.ly/BW_AnniversaryFilm

– Picture is available at AP –

The issuer is solely responsible for the content of this announcement.

Virtual IT Group and The Instillery Go to Town on Zero Trust

By
Advertorial Desk
-

SHELLHARBOUR, Australia , Sept. 15, 2025 /PRNewswire/ — On the eve of Zscaler‘s Annual Australasian Zenith Live conference, Virtual IT Group is excited to announce the formation of a specialist Zero Trust practice. This initiative is enabled by its recent integration with New Zealand-based MSP The Instillery. 

The announcement follows on the heels of the trans-Tasman merger between Virtual IT Group and The Instillery which has already positioned the combined entity as one of the largest managed services and security providers operating in the region.  

“One of the key reasons we were attracted to The Instillery was their depth of capability in Zero Trust and their partnership with Zscaler,” said Virtual IT Group Founder and CEO Christian Pacheco. 

Pacheco added, “Our intention is to take a Zero Trust capability to market immediately by leveraging the Zscaler partnership and adding to our team internally. There is a massive unmet need in this space—among customers still relying on legacy security architectures, as well as those not realising the full value of their current Zero Trust investments.”

Eric Swift, Vice President & Managing Director, Zscaler Australia and New Zealand, said, “The collaboration between Virtual IT Group and The Instillery signals a pivotal moment for Zero Trust adoption across Australia and New Zealand.”

Swift added, “With cyber threats becoming increasingly sophisticated and legacy architectures struggling to keep pace, the combined expertise of these MSPs, alongside Zscaler Zero Trust ExchangeTM platform, will empower organisations to confidently modernise their security ecosystems and safeguard critical data without compromise.”

Instillery Group COO Jeremy Nees is driving the new Zero Trust practice across Australian and New Zealand with key new hires to be announced in the coming weeks. 

ENDS

About Virtual IT Group

Virtual IT Group is one of the fastest growing and capable MSP & MSSP providers in Australia and New Zealand. With scale, reach, and proven expertise, we deliver end-to-end managed services for infrastructure as well as security, cloud transformation, and modern workplace solutions that keep organisations productive, resilient, and secure – real cyber solutions for real cyber threats. 

www.vitg.com.au

IVD Medical Holding Limited Releases “ETHK” Ecosystem Vision: Technology for the Public, Chain for the Way On September 14

By
Advertorial Desk
-

NEW YORK, US – Media OutReach Newswire – 14 September 2025 – IVD Medical Holding Limited (01931.HK) officially announced its name change. Its English name was changed to “ETHK Labs Inc.”. This move marks a comprehensive strategic upgrade, shifting the company’s focus to core technology research and development and output for the digital industry and on-chain financial ecosystem. Through this name change, IVD Medical Holding Limited aims to more accurately reflect its new position as a key technology provider for the “ETHK” on-chain financial ecosystem and further enhance the group’s competitiveness and influence in the global digital asset ecosystem.

Hashtag: #IVDMedical

The issuer is solely responsible for the content of this announcement.

IVD Medical Holding Limited and ETHK Group Establish Joint Venture, On-Chain Financial Strategy Upgraded On September 14

By
Advertorial Desk
-

NEW YORK, US – Media OutReach Newswire – 14 September 2025 – IVD Medical Holding Limited (01931.HK) released an announcement stating its collaboration with ETHK Group, a global on-chain financial ecosystem investment holding group, to jointly establish two new companies, ETHK Inc and ETHK HOLDINGS LIMITED. ETHK Group focuses on building a global on-chain financial ecosystem, and its global perspective and ecosystem resources will provide critical support for the joint venture’s initial development. This collaboration is a strategic upgrade of IVD Medical Holding Limited’s “building RWA platform technology ecosystem” and “exploring on-chain finance” initiatives. It marks a leap from focusing on RWA trading technology to covering the entire on-chain financial ecosystem, including underlying technology, asset classes, and global compliance, with the potential to seize the global trend of digitalizing financial assets and open up a new growth curve.
Hashtag: #IVDMedical

The issuer is solely responsible for the content of this announcement.

HKUST Deepens Sweden Ties Positioning Hong Kong as a Strategic Nexus for Sino-Swedish Innovation

By
Advertorial Desk
-

HONG KONG, Sept. 14, 2025 /PRNewswire/ — A high-level delegation from The Hong Kong University of Science and Technology (HKUST), led by President Professor Nancy Ip, has successfully concluded a strategic visit to Sweden, forging deeper partnerships with the country’s leading academic and research institutions. The visit reinforced Hong Kong’s role as a vital bridge for scientific and technological collaboration between Sweden and China, with a focus on advancing innovation in fields such as life sciences, HealthTech, ageing, energy, robotics, and sustainability.

Building on a Foundation of Sino-Swedish Collaboration

The visit builds on the longstanding partnership between Sweden and China, marked by decades of diplomatic, industrial, and scientific cooperation. As a global leader in innovation, Sweden’s ecosystem of world-class research and industry applications aligns seamlessly with HKUST’s mission to drive cutting-edge research and connect global innovation networks. By leveraging Hong Kong’s strategic position, HKUST serves as a dynamic conduit for linking Sweden’s innovation strengths with China’s vast research capabilities and market potential, fostering impactful Sino-Swedish collaboration.

Synergizing Sweden’s Innovation Ecosystem with HKUST’s Research & Innovation Excellence

Sweden is renowned as a global leader in innovation, consistently ranking among the world’s most competitive knowledge economies. Its unique model integrates academic research, industry innovation, and government investment in strategic fields. HKUST is a natural partner in this ecosystem, complementing Sweden’s strengths not only with world-class research excellence but also with a powerful, action-oriented drive for innovation. This is evidenced by its distinguished track records for founding unicorn startups and translating research into tangible impact, particularly in life sciences, HealthTech, ageing, energy, robotics, and sustainability. The shared commitment to turning pioneering ideas into real-world solutions creates powerful synergies for transformative research and development.

Strategic Engagements and Future Collaboration Framework

The visit builds on existing partnerships, including robust student exchanges and a strong history of collaborative research, to drive innovation in areas of global significance. The HKUST delegation engaged in high-level strategic dialogues with Sweden’s premier institutions, including the Royal Swedish Academy of Engineering Sciences (IVA), Karolinska Institutet, and KTH Royal Institute of Technology. These discussions laid the foundation for a robust framework to advance collaborative research, talent development, and innovation. Key objectives include:

  • Strengthening joint research initiatives in life sciences, HealthTech, ageing, energy, robotics, sustainability, and other areas of mutual interest.
  • Expanding scholar exchange programs and collaborative educational opportunities.
  • Facilitating innovation commercialization and technology transfer between Europe and Asia.

Leadership Perspective on Global Innovation

President Professor Nancy Ip highlighted HKUST’s pivotal role in the Swedish partnerships: “Sweden’s innovation ecosystem is a global benchmark, and its historic ties with China provide a strong foundation for collaboration. HKUST is uniquely positioned to serve as the academic engine and connector in this relationship, fostering a strategic innovation corridor between Sweden and the Greater Bay Area.”

“By combining Sweden’s research and industrial leadership with HKUST’s dynamic research environment and China’s technological scale, we are accelerating breakthroughs that address global challenges. This partnership underscores Hong Kong’s role as a leading international innovation hub,” President Ip added.

This enhanced collaboration paves the way for transformative research, talent development, and innovation by strategically leveraging the Greater Bay Area—home to the world’s top-ranked Guangzhou–Hong Kong–Shenzhen innovation cluster according to the World Intellectual Property Organization’s (WIPO) Global Innovation Index 2025.

Download photos here: https://bit.ly/4poceSO

SingPost Launches Lower-Cost U.S. Shipping for Retail Customers, Supporting Compliance with New Rules

By
Advertorial Desk
-
  • Speedpost Direct International (Retail) offers a Delivery Duty Paid (DDP) solution that helps retail senders comply with the latest regulations, providing transparency and simplicity at every step
  • Businesses including corporations, SMEs, marketplace sellers, encouraged to use corporate Speedpost Direct International for more flexibility and dedicated account management

SINGAPORE, Sept. 14, 2025 /PRNewswire/ — Singapore Post Limited (SingPost) will be launching Speedpost Direct International (Retail) for retail customers on 15 September 2025. This is a new solution designed in direct response to recent changes in the United States (U.S.) import regulations which removed de minimis exemptions for shipments.

The new service builds on the corporate-only launch of Speedpost Direct International, ensuring retail, walk-in customers to SingPost’s post offices now have access to a compliant shipping channel under the new U.S. customs regulations.

Fixed shipping rates for packages up to 2kg

Speedpost Direct International (Retail) enables retail customers to conveniently send parcels to the U.S. using one of two standard packaging options: an envelope or a box, both provided by SingPost at a flat shipping rate.

Customers with existing packaging will still have their items repacked into the standard envelope or box to ensure compliance and facilitate efficient handling.

Speedpost Direct International (Retail) has a flat shipping rate of:

  • S$29 for items up to 0.5kg that fit into the standard envelope (16.2 x 22.9cm) or
  • S$69 for the standard box (31 x 23 x 9cm) for items up to 2kg
  • Each shipment’s value must not exceed more than US$100

“The core benefit of this service is its transparency for retail customers,” said Neo Su Yin, Group Chief Operating Officer, SingPost. “Our post office staff will assist customers in calculating and collecting all necessary duties and taxes upfront, eliminating the surprise of unexpected fees for the recipient. This provides a hassle-free experience from start to finish.”

The two standard packaging options provided by SingPost at a flat shipping rate covers over 80 per cent of the typical size of SingPost’s shipments to the U.S. For customers with more frequent or varied shipping needs, SingPost recommends setting up a corporate account where dedicated account managers can support customers with shipments of different sizes using Speedpost Direct International.

At the post office, for packages above 2kg or valued more than US$100, customers may use the premium Speedpost Express International service instead. Speedpost Express International is a premium service which has express delivery services for delivery to the U.S. within 3-6 days, compared to the more economical, but slightly longer delivery within 8 days for Speedpost Direct International.

Infographic on all SingPost services sending to the U.S.
Infographic on all SingPost services sending to the U.S.

Key Steps for Senders @ Post Offices 

To ensure a smooth and efficient process at the post office, customers using the new service must have the following prepared:

  • Item(s) for Shipment: Bring your item(s) to be shipped. To ensure compliance, all items will be repackaged into either the standard envelope or small box, regardless of any existing packaging materials
  • Country of Origin: Know the country where your item was manufactured. This is a new mandatory requirement for U.S. customs
  • HS Code: Have the Harmonised System (HS) Code for your item ready. This 10-digit code is a universal classification for products and is now mandatory for customs clearance. If you do not know the HS Code, our staff will assist you in finding the correct one
  • Recipient Information: Provide the full and correct name, address, and contact number of the recipient in the U.S. to ensure accurate delivery

Background to the U.S. Regulatory Changes

This launch follows a significant shift in U.S. customs policy, which on 29 August 2025, suspended the “de minimis” exemption. This exemption previously allowed most international shipments valued under US$800 to enter the U.S. without duties or taxes. The change now subjects all commercial items to duties, taxes, and enhanced scrutiny, which the traditional postal system is not equipped to handle.

To protect customers from potential delays or parcel seizure, SingPost made the proactive decision to suspend standard postal services for commercial items to the U.S. This new suite of Speedpost Direct International services provides a compliant and reliable alternative while the postal networks continue to adapt to the new requirements.

About Singapore Post Limited (SingPost)

Singapore Post (SingPost) is a leading postal and eCommerce logistics provider in Asia Pacific. The portfolio of businesses spans from national and international postal services to warehousing and fulfilment, international freight forwarding and last mile delivery, serving customers in more than 220 global destinations. Headquartered in Singapore, SingPost has approximately 3,000 employees, with presence in 14 markets worldwide. Since its inception in 1858, the Group has evolved and innovated to bring about best-in-class integrated logistics solutions and services, making every delivery count for people and planet. www.singpost.com

HIKSEMI Lights Up UTAR Kampar Campus with “Glow. Grow. Store It All” Campaign

By
Advertorial Desk
-

KAMPAR, Malaysia, Sept. 14, 2025 /PRNewswire/ — HIKSEMI, a global innovator in storage solutions for industrial control, video surveillance, data centers, and consumer electronics, recently energized the Universiti Tunku Abdul Rahman (UTAR) Kampar campus with a dynamic series of events under the theme “Glow. Grow. Store It All”. More than a reference to the vibrant RGB lighting of its high-performance storage products, the campaign symbolizes HIKSEMI’s deeper mission: to illuminate the inner glow of personal growth, learning, and memory, empowering students not just as users, but as individuals on a journey.


Held from September 10 to 14, the initiative began with a technical seminar demystifying smart storage technologies, real-world industry applications, and future career opportunities in the digital infrastructure sector. The event included a visit to UTAR’s Faculty of Computing and Information Technology, where HIKSEMI explored potential collaborations on network research and data center storage upgrades, reinforcing its commitment to academic-industry synergy.

From September 13 to 14, HIKSEMI took center stage at the university’s charity carnival, donating storage products worth RM50,000 to support students and faculty. The interactive booth showcased HIKSEMI’s full portfolio, including the award-winning D300 SSD, recognized as the 2025 Global Flash Memory Summit’s “SSD Product of the Year,” the rugged Guard series for surveillance, and popular consumer lines such as the gaming-focused FUTURE PCIe 5.0 SSD with speeds up to 14,800MB/s, more than double that of PCIe 4.0. Also on display were the CAPTURE series for photography enthusiasts and the sleek, student-friendly WAVE Series. Through on-site challenges and a short video contest, students shared their personal “glow moments,” highlighting how HIKSEMI preserves the key milestones of their academic and personal journeys.

This outreach reflects HIKSEMI’s strategic focus on Southeast Asia, where it ranks among the top three storage brands in Thailand and partners with icons like esports legend Mushi and Malaysia’s elite Boom Esports team to connect with Gen Z audiences.

“Glow. Grow. Store It All” is more than a slogan. It is a promise to innovate relentlessly, empower youth, and ensure every moment of brilliance is captured and cherished.

1...2,3082,3092,310...6,343Page 2,309 of 6,343